Advanced BioMedical Technologies' PA Absorbable Orthopaedic Implant Screw human clinical tests completed

Advanced BioMedical Technologies Inc. (OTCBB: ABMT) announced that it has completed all 60 human clinical test cases of its PA Absorbable Orthopaedic Implant Screw according to the regulations set out by the China State Food and Drug Administration (SFDA). The actual number of test cases that have been taken in is 63. The Company is compiling trial reports and has entered the last stage of its clinical trial. The Company will apply for the SFDA final approval of this product as soon as the Comparison Data are prepared.

"The successful taking in of 63 clinical test cases that were conducted at SFDA appointed hospitals is a milestone in our company's history. It symbolizes the approval of our technology by hospitals and doctors, and the acknowledgement and acceptance of our product by patients. We will commence production and marketing of our product as soon as we receive SFDA approval," said Ms Hui Wang, CEO of Advanced BioMedical Technologies Inc.

A Post Clinical Test Summary Conference for Advanced BioMedical Technologies Inc.'s PA Orthopaedic Implant Screw and Wire was held in Teng Chun City, Yunnan Province, China during September 9 to 12. Twenty-five medical specialists and doctors from eight SFDA appointed GCP (Good Clinical Practice) hospitals attended this meeting. Speakers from each hospital presented their clinical test summary reports to the audience.

Source:

Advanced BioMedical Technologies Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals surge in e-scooter injuries in Denver and increased hospital admissions